{"disease":{"id":"leptomeningeal-melanoma","name":"leptomeningeal melanoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03025256","title":"Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07414979","title":"Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":8,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}